[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424. [2]McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread[J]. Am J Surg Pathol, 1988, 12:897-906. [3]Chen T, Wang F, Chen H, et al. Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems[J]. BMC Urol, 2022, 22:64. doi:10.1186/s12894-022-01013-8. [4]唐杰,汪娜,李欣,等. 经直肠超声引导穿刺活检研究前列腺外周带增生[J]. 中华超声影像学杂志, 2004, 13:121-123. [5]薛念余,程跃,张盛敏,等. 经直肠剪切波弹性成像技术在前列腺外周带低回声结节诊断中的价值[J]. 中华泌尿外科杂志, 2019, 40:62-63. [6]Li Y, Tang J, Fei X, et al. Diagnostic performance of contrast enhanced ultrasound in patients with prostate cancer:a meta-analysis[J]. Acad Radiol,2013,20:156-164. [7]Bono AV, Celato N, Cova V, et al. Microvessel density in prostate carcinoma[J]. Prostate Cancer Prostatic Dis, 2002, 5: 123-127. [8]Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2021, 79:243-262. [9]Jung EM, Wiggermann P, Greis C, et al. First results of endocavity evaluation of the microvascularization of malignant prostate tumors using contrast enhanced ultrasound (CEUS) including perfusion analysis: first results[J]. Clin Hemorheol Microcirc, 52:167-177. [10]徐辉雄,郭乐杭.前列腺超声造影临床应用指南(2012)解读[J].中华医学超声杂志(电子版),2014,11:105-107. |